openPR Logo
Press release

Ovarian Cancer - Pipeline Review, H2 2016, Pharmaceutical and Healthcare

01-04-2017 11:38 AM CET | Health & Medicine

Press release from: Ovarian Cancer

Ovarian Cancer - Pipeline Review, H2 2016, Pharmaceutical

"Ovarian Cancer - Pipeline Review, H2 2016" The Report covers current Market Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Get Sample Report With TOC @ https://goo.gl/JxlsyO

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 15, 115, 119, 7, 195, 31 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 11, 34 and 8 molecules, respectively.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Researchmoz Global Pvt. Ltd.
90 State Street,
Albany, NY 12207,
United States,
Tel: 866-997-4948 (Us-Canada Toll Free),
Tel: +1-518-621-2074

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ovarian Cancer - Pipeline Review, H2 2016, Pharmaceutical and Healthcare here

News-ID: 405266 • Views: 195

More Releases from Ovarian Cancer

Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Fron …
Researchmoz added Most up-to-date research on "Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Frontier Pharma" to its huge collection of research reports. Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is
Ovarian Cancer - US Market Insights, Epidemiology and Market Forecast-2020
ALBANY, NY, April 6, 2017 : DelveInsights Ovarian Cancer - Market Insights, Epidemiology and Market Forecast-2020- US Reports provides an overview of the disease and global market size of the Ovarian Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Ovarian Cancer from 2012-2020. According to DelveInsight, the forecasted patient population of Ovarian cancer will decrease at a CAGR
Recent Study on Ovarian Cancer Identifying and Commercializing First-in-Class In …
Researchmoz added Most up-to-date research on "Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports. Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is
Therapeutics Development For Ovarian Cancer - Pipeline Insights, 2017
Researchmoz added Most up-to-date research on "Therapeutics Development For Ovarian Cancer - Pipeline Insights, 2017" to its huge collection of research reports. DelveInsights, Ovarian Cancer -Pipeline Insights, 2016, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Ovarian Cancer. Ovarian cancer is the sudden growth of the cells

All 5 Releases


More Releases for Oncology

Immuno Oncology Assays Market Size, Immuno Oncology Assays Market Prediction, Im …
The Immuno Oncology Assays Market Report examines the Immuno Oncology Assays industry from a variety of angles, including market size, status, trends, and forecasts. It also gives a quick rundown of the top competitors and development opportunities in the market. The research contains a comprehensive study of the keyword market, split by companies, regions, types, and applications. The research goes into great detail on several aspects that have been studied as
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Allied Academies was founded by Jim and JoAnn Carland and
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Allied Academies was founded by Jim and JoAnn Carland and
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Allied Academies was founded by Jim and JoAnn Carland and
International Oncology Summit
Allied Academies invites all the participants from all over the world to attend 'International Oncology Summit’ during November 27-28, 2017 in Atlanta, Georgia, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. This Summit has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. International Oncology Summit will have an anticipated